Regeneron Enters into Asset Purchase Agreement to Acquire 23andMe® for $256 Million; Plans to Maintain Consumer Genetics Business and Advance Shared Goals of Improving Human Health and Wellness

Core Viewpoint - Regeneron Pharmaceuticals has successfully bid for the assets of 23andMe Holding Co. for $256 million, aiming to enhance its leadership in genetics-guided research and drug development, pending bankruptcy court and regulatory approvals [1][2][3] Group 1: Acquisition Details - The planned acquisition includes 23andMe's Personal Genome Service, Total Health and Research Services, and Biobank assets, with the transaction expected to close in Q3 2025 [1] - Regeneron will operate 23andMe as a wholly owned subsidiary, continuing its consumer genomics services while excluding the Lemonaid Health business from the purchase [3][4] Group 2: Commitment to Data Privacy - Regeneron emphasizes its commitment to the privacy and ethical use of 23andMe's customer data, planning to work with an independent Customer Privacy Ombudsman to ensure compliance with privacy policies and laws [2][3] - The company has a proven track record in large-scale data management, having linked deidentified DNA sequences from nearly three million participants to electronic health records [2][3] Group 3: Strategic Vision - Regeneron aims to leverage its expertise in genetic research to support 23andMe's mission of helping individuals understand their DNA and improve personal health [2][3] - The acquisition aligns with Regeneron's broader strategy to utilize genetics research for advancing medical treatments and improving societal health outcomes [2][3][4]